These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28331041)

  • 1. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    van der Werf MJ; Hollo V; Ködmön C; Dara M; Catchpole M
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Chee CBE; KhinMar KW; Sng LH; Jureen R; Cutter J; Lee VJM; Wang YT
    Eur Respir J; 2017 Aug; 50(2):. PubMed ID: 28798092
    [No Abstract]   [Full Text] [Related]  

  • 3. Childhood multidrug-resistant tuberculosis in the European Union and European Economic Area: an analysis of tuberculosis surveillance data from 2007 to 2015.
    Ködmön C; van den Boom M; Zucs P; van der Werf MJ
    Euro Surveill; 2017 Nov; 22(47):. PubMed ID: 29183553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment duration for patients with drug-resistant tuberculosis, United States.
    Winston CA; Mitruka K
    Emerg Infect Dis; 2012 Jul; 18(7):1201-2. PubMed ID: 22709909
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-resistance--a challenge for tuberculosis control in the European Union and European Economic Area.
    van der Werf MJ; Sprenger M
    Euro Surveill; 2014 Mar; 19(11):. PubMed ID: 24679718
    [No Abstract]   [Full Text] [Related]  

  • 6. Is Shorter Treatment Regimen for Multidrug-resistant Tuberculosis feasible in Indian Children?
    Shah I
    Indian Pediatr; 2017 Feb; 54(2):160. PubMed ID: 28285296
    [No Abstract]   [Full Text] [Related]  

  • 7. Changing the game for multidrug-resistant tuberculosis.
    Ghanashyam B
    Lancet; 2016 Mar; 387(10024):1149-50. PubMed ID: 27025324
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of drug-resistant tuberculosis.
    Lange C; Dheda K; Chesov D; Mandalakas AM; Udwadia Z; Horsburgh CR
    Lancet; 2019 Sep; 394(10202):953-966. PubMed ID: 31526739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidrug-resistant/extensively drug-resistant tuberculosis in Greece: predominance of Mycobacterium tuberculosis genotypes endemic in the Former Soviet Union countries.
    Ioannidis P; van Soolingen D; Mokrousov I; Papaventsis D; Karabela S; Konstantinidou E; Marinou I; Nikolaou S; Kanavaki S; Mantadakis E; Samonis G; Anthony R; Vogiatzakis E
    Clin Microbiol Infect; 2017 Dec; 23(12):1002-1004. PubMed ID: 28698038
    [No Abstract]   [Full Text] [Related]  

  • 10. European expansion. Outwitting TB on the E.U.'s eastern frontier.
    Enserink M
    Science; 2004 Apr; 304(5668):199. PubMed ID: 15073353
    [No Abstract]   [Full Text] [Related]  

  • 11. A new treatment for drug-resistant tuberculosis in Ukraine.
    Holt E
    Lancet Infect Dis; 2022 Jan; 22(1):23. PubMed ID: 34953550
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of contacts of multidrug-resistant tuberculosis patients in the European Union and European Economic Area.
    van der Werf MJ; Sandgren A; Manissero D
    Int J Tuberc Lung Dis; 2012; 16(3):426. PubMed ID: 22640458
    [No Abstract]   [Full Text] [Related]  

  • 13. Extensive drug-resistant TB: a threat for Europe?
    Manissero D; Fernandez de la Hoz K
    Euro Surveill; 2006 Sep; 11(9):E060928.2. PubMed ID: 17075155
    [No Abstract]   [Full Text] [Related]  

  • 14. [Spread of multidrug resistance of Mycobacterium and its impact on the efficiency of treatment in patients with tuberculosis in the penitentiaries of the Arkhangelsk Region].
    Mar'iandyshev AO; Nizovtseva NI; Glomozda PG; Panasik VP; Duginova TN; Kuznetsov AA
    Probl Tuberk Bolezn Legk; 2005; (5):19-21. PubMed ID: 15988972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Now is the time for shorter all-oral regimens for multidrug-resistant tuberculosis.
    Seung KJ; Hewison C
    Lancet Glob Health; 2019 Jun; 7(6):e706. PubMed ID: 31005492
    [No Abstract]   [Full Text] [Related]  

  • 16. Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone.
    Singh PK; Jain A
    Emerg Infect Dis; 2019 Sep; 25(9):1760-1762. PubMed ID: 31441763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shorter & cheaper regimen to treat multidrug-resistant tuberculosis: A new hope.
    Prasad R; Gupta N; Banka A
    Indian J Med Res; 2017 Sep; 146(3):301-303. PubMed ID: 29355135
    [No Abstract]   [Full Text] [Related]  

  • 18. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016.
    Mustazzolu A; Borroni E; Cirillo DM; Giannoni F; Iacobino A; ; Fattorini L
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29724919
    [No Abstract]   [Full Text] [Related]  

  • 19. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 20. Shorter regimen for multi drug resistant tuberculosis cures more than 80% of patients.
    Cousins S
    BMJ; 2016 Oct; 355():i5807. PubMed ID: 27789468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.